Table 2.
Hazard ratio (HR) and 95% Confidence Interval (CI) of the association of glucose-lowering therapies, and overall mortality in diabetic pancreatic cancer patients.
| Variable | Multivariate-Adjusted HR * (95% CI) | p-Value |
|---|---|---|
| Gender | ||
| Male | 1.00 | ref. |
| Female | 0.86 (0.70–1.05) | 0.13 |
| Age at diagnosis | ||
| <60 | 1.00 | ref. |
| 60–69 | 1.02 (0.72–1.43) | 0.91 |
| 70–79 | 1.44 (1.02–2.04) | 0.04 |
| 80+ | 2.07 (1.40–3.06) | <0.001 |
| TNM stage | ||
| I | 1.00 | ref. |
| II | 0.99 (0.62–1.59) | 0.97 |
| III | 1.43 (0.88–2.31) | 0.15 |
| IV | 2.80 (1.81–4.35) | <0.001 |
| Missing | 1.30 (0.80–2.10) | 0.29 |
| Histology | ||
| Adenocarcinoma | 1.00 | ref. |
| Other | 0.91 (0.60–1.37) | 0.66 |
| Neuroendocrine | 0.27 (0.15–0.48) | <0.001 |
| Not specified | 1.26 (1.01–1.58) | 0.04 |
| Antihyperglycemic medications | ||
| Sulfonylurea | 1.00 | ref. |
| Metformin | 0.80 (0.59–1.09) | 0.15 |
| Sulfonylurea and metformin | 0.79 (0.61–1.02) | 0.08 |
| Metformin and other medications | 0.94(0.68–2.29) | 0.69 |
| Insulin | 1.31 (0.83–2.04) | 0.24 |
| Other medications | 0.61 (0.36–1.03) | 0.07 |
* Adjusted for all variables shown in table.